Articles in Scholarly Journals [Incomplete List]

1. C-Peptide and Its C-Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients
   Experimental Diabetes Research, vol. 2008, Article ID 730594, 6 pages, 2008
2. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
   British Journal of Clinical Pharmacology, vol. 64, no. 1, pp. 75–82, 2007
3. Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive ProteinThe PIOSTAT Study
   Journal of the American College of Cardiology, vol. 49, no. 3, pp. 290–297, 2007
4. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study
   Metabolism, vol. 56, no. 4, pp. 491–496, 2007
5. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapyâ??
   Journal of Diabetes and its Complications, vol. 20, no. 3, pp. 145–152, 2006
6. Response to Jean-Luc Cracowski, Gregg R. McCord, Christopher T. Minson
   Journal of Diabetes and its Complications, vol. 20, no. 2, pp. 134–135, 2006
7. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride
   Metabolism, vol. 55, no. 1, pp. 20–25, 2006
8. Therapie der diabetischen Polyneuropathie
   Der Diabetologe, vol. 2, no. 2, pp. 114–124, 2006
9. Evaluation of CGMSR During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes
   Diabetes Technology Therapeutics, vol. 8, no. 2, pp. 146–155, 2006
10. High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus
    Diabetes Technology Therapeutics, vol. 8, no. 1, pp. 28–36, 2006
11. Impact of Environmental Temperature on Skin Thickness and Microvascular Blood Flow in Subjects With and Without Diabetes
    Diabetes Technology Therapeutics, vol. 8, no. 1, pp. 94–101, 2006
12. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
    Current Medical Research and Opinion, vol. 22, no. 6, pp. 1211–1215, 2006
13. Association of high-sensitive C-reactive protein with advanced stage ?-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
    Clinical Chemistry and Laboratory Medicine, vol. 44, no. 5, pp. 556–560, 2006
14. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality
    Expert Opinion on Pharmacotherapy, vol. 7, no. 4, pp. 463–476, 2006
15. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects
    Expert Review of Cardiovascular Therapy, vol. 4, no. 4, pp. 445–459, 2006
16. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism
    Expert Opinion on Drug Delivery, vol. 2, no. 6, pp. 1097–1106, 2005
17. IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design
    Diabetes Technology Therapeutics, vol. 7, no. 3, pp. 478–486, 2005
18. Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study
    Circulation, vol. 111, no. 19, pp. 2525–2531, 2005
19. Influence of Glucose Control and Improvement of Insulin Resistance on Microvascular Blood Flow and Endothelial Function in Patients with Diabetes Mellitus Type 2
    Microcirculation, vol. 12, no. 7, pp. 543–550, 2005
20. Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic ControlResults From the Pioneer Study
    Journal of the American College of Cardiology, vol. 45, no. 12, pp. 1925–1931, 2005
21. Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Journal of Diabetes and its Complications, vol. 19, no. 3, pp. 128–132, 2005
22. Effects of C-peptide on Microvascular Blood Flow and Blood Hemorheology
    Experimental Diabesity Research, vol. 5, no. 1, pp. 51–64, 2004
23. Evaluation of SET-A New Device for the Measurement of Pain Perception in Comparison to Standard Measures of Diabetic Neuropathy
    Diabetes Technology Therapeutics, vol. 6, no. 5, pp. 601–606, 2004
24. IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes
    Diabetic Medicine, vol. 21, no. 10, pp. 1149–1153, 2004
25. Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes
    Diabetes Care, vol. 27, no. 3, pp. 682–687, 2004
26. Clinical and Laboratory Evaluation of Specific Chemiluminescence Assays for Intact and Total Proinsulin
    Clinical Chemistry and Laboratory Medicine, vol. 41, no. 9, pp. 1234–1238, 2003
27. Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes
    Experimental and Clinical Endocrinology & Diabetes, vol. 111, no. 2, pp. 97–103, 2003
28. Pilot Study with Technosphere/PTH(1 - 34) - A New Approach for Effective Pulmonary Delivery of Parathyroid Hormone (1 - 34)
    Hormone and Metabolic Research, vol. 35, no. 5, pp. 319–323, 2003
29. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide
    Nitric Oxide, vol. 9, no. 2, pp. 95–102, 2003
30. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study
    Diabetic Medicine, vol. 19, no. 11, pp. 900–909, 2002
31. Response to Jungheim and Koschinsky
    Diabetes Care, vol. 25, no. 3, pp. 638–639, 2002
32. Effect of C-Peptide on Glucose Metabolism in Patients With Type 1 Diabetes
    Diabetes Care, vol. 25, no. 6, pp. 1096–1097, 2002
33. Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes: The EURODIAB Complications Study
    Diabetes Care, vol. 24, no. 2, pp. 316–322, 2001
34. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study
    Diabetic Medicine, vol. 18, no. 1, pp. 59–67, 2001
35. The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus
    Diabetic Medicine, vol. 18, no. 6, pp. 489–494, 2001
36. Schnell wirkende Insulinanaloga: Neue Wirkstoffe für die Diabetes-Therapie
    Pharmazie in unserer Zeit, vol. 30, no. 2, pp. 118–123, 2001
37. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I
    Clinical Science, vol. 98, no. 3, p. 283, 2000
38. Carbohydrate sources and glycaemic control in Type 1 diabetes mellitus
    Diabetic Medicine, vol. 17, no. 5, pp. 351–359, 2000
39. Serum levels of substance P are decreased in patients with type 1 diabetes
    Experimental and Clinical Endocrinology & Diabetes, vol. 108, no. 3, pp. 164–167, 2000
40. Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements
    Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 5, pp. 1890–1894, 2000
41. a-Lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products
    Clinical Science, vol. 96, no. 1, p. 75, 1999
42. The physiological impact of proinsulin C-peptide
    Pathophysiology, vol. 5, no. 4, pp. 257–262, 1999
43. Elevated serum leptin concentrations in type 2 diabetic patients with microalbuminuria and macroalbuminuria
    Metabolism, vol. 48, no. 10, pp. 1290–1293, 1999
44. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus
    Diabetologia, vol. 42, no. 4, pp. 465–471, 1999
45. Is there an ectopic secretion of monomeric calcitonin in the human being?
    Langenbeck's Archives of Surgery, vol. 383, no. 6, pp. 456–459, 1998
46. Comparison of the microvascular response to transcutaneous electrical nerve stimulation and postocclusive ischemia in the diabetic foot
    Journal of Diabetes and its Complications, vol. 11, no. 5, pp. 291–297, 1997
47. Decreased sympatho-adrenal activity in diabetic patients with autonomic dysfunction following mental stress
    Journal of the Autonomic Nervous System, vol. 61, no. 1, pp. 31–36, 1996